Solvay Pharma Россия и СНГ Обратная связь Карта сайта
Четверг, 26 июня 2008 г.
Сделать стартовойДобавить в избранноеСообщить о странице другуW@PAvantGoPDA
В стремлении к прогрессу, с заботой о людях
Фемостон
Регистрация
Бесплатный доступ к сайту
XV Российский национальный конгресс "Человек и лекарство"

Библиография

  1. Miller VT, Muesing RA, LaRosa JC, Stoy DB, Philips EAr Stillman RJ. Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-density lipoprotein subtractions and apolipoprotein A-l. Obstet Gynecol 1991;77:235-240.
  2. Whitehead Ml, Hillard TC, Crook D. The role and use of progestogens. Obstet Gynecol 1990;75 (Suppl.):S59-S76.
  3. van de Weijer PHM, Barentsen RF Kenemans R Women's expectations and acceptance of cyclic induced HRT bleeds. Maturitas 1998;30:257-263.
  4. Ettinger B, Pressman A, Silver R Effect of age on reasons for initiation and discontinuation of hormone replacement therapy. Menop 1999:6:282-289.
  5. Rozenbaum.H. Relationships between chemical structure and biological properties of progestogens. Am J Obstet Gynaecol 1982;142:719-724.
  6. Kuhl H. Pharmacokinetics of oestrogens and progestogens. Maturitas 1990:12:171-197.
  7. Scholer HFLr De Wachter AM. Biological properties of 9,10-isomeric steroids. I. Progestational activity of 9fl,10a-steroids. Ada Endocrinol 1960:35:188-196.
  8. Reerink EH, Scholer HFL, Westerhof R Querido A, Kassenaar AAH, Diczfalusy E, Tillinger KG. A new class of hormonally active steroids. Nature 1960:186:168-169.
  9. Tausk M. A general summary of dydrogesterone, a derivative of retro-progesterone. In: Tausk M, ed. International Encyclopaedia of Pharmacology and Therapeutics. Section 48. Pharmacology of the Endocrine System and Related Drugs: Progesterone, Progestational Drugs and Antifertility Drugs. Volume II. Pergamon Press: Oxford, New York, 1972:481.
  10. Claasen V, Morsink L, De Wachter AM. Influence of dydrogesterone (6-dehydroretroprogesterone, Duphaston®) on ovulation in the rat, rabbit and monkey. Ada Endocrinol 1971:67:551-562.
  11. Marois M. Action d'un progestatif actif par voie buccale, la dydrogesterone, sur la come uterine de la lapine. Bulletin de L'Academie Nationale de Medecine 1962:146:324-328.
  12. Marois M. Absence de proprietes masculinisantes ou feminisantes d'un progestatif actif per os, la dydrogesterone, chez le rat male ou femelle adulte et chez le foetus de rat [The absence of masculinising or feminising properties of an orally active progestogen, dydrogesterone, in adult male and female rats and in rat foetuses]. Bulletin de L'Academie Nationale de Medecine 1962;146:354-364.
  13. Boris A, Stevenson RH, Timal T. Some studies on the endocrine properties of dydrogesterone. Steroids 1966:7:1-10.
  14. Lane G, Siddle N, Ryder ТА, Pryse-Davies J, King RJB, Whitehead Ml. Effects of dydrogesterone on the oestrogenized postmenopausal endometrium. Br J Obst Gynaecol 1986:93:55-62.
  15. Morsink L, De Wachter AM. Dydrogesterone {Duphaston") and the "early-androgen syndrome". Solvay Duphar Data on File Report No 56649/32/701970.
  16. Vomachka AJ, Paup DC, Coniglio LR McManus MF, Clemens LG. Progestin-induced pseudohermaphroditism in the female hamster. J Reprod Pert 1974;37:269-276.
  17. MacDonald GJ. Maintenance of pregnancy in ovariectomised rats with steroid analogues and the reproductive ability of progeny. Biol Reprod 1982:27:261-267.
  18. Vermorken AJM, Sultan CH, Goos CMAA. Dydrogesterone has no peripheral (anti)-androgenic properties. In Vivo 1987; 1:167-172.
  19. Scholer HFL, De Wachter AM. Evaluation of the androgenic properties of progestational compounds in the rat by the female foetal masculini-sation test. Acta Endocrinol 1961:38:128-136.
  20. Suchowsky GK, Turolla E, Arcari G. Studies of the so-called virilizing effects of steroids in female rat fetuses. Endocrinol 1967:80:255-262.
  21. Scholer HFL. Maintenance of pregnancy in spayed animals with 6-dehydro-retro-progesterone, and masculinisation of the female foetus as a test for androgenic activity of progestational compounds. J Endocrinol 1962:24:15-16.
  22. Jost A. Maintien de la gestation chez la lapine par un ste're'o-isomere voisin de la progesterone (6-dehydro-retro-progesterone). Action sur le foetus. Ada Endocrinol 1963;43:539-544.
  23. Wambach G, Helber A. Structure-affinity relationship of antimineralo-corticoid active steroids. In: Agarwal MK, ed. Hormone antagonists. Berlin, New York: Walter de Gruyten and Company, 1982:293-305.
  24. Verhaar HJJ, Damen CA, Duursma SA, Scheven BAA. A comparison of the action of progestins and estrogen on the growth and differentiation of normal adult human osteoblast-like cells in vitro. Bone 1994; 15:307-311.
  25. WHO-IARC. Monographs on the evaluation of the carcinogenic risk of chemicals to humans, sex hormones (II). December 1979;21.
  26. WHO-IARC. Monographs on the evaluation of the carcinogenic risk of chemicals to humans. October 1982; 1-29.
  27. Keller JG. Acute oral administration of SAD 121 to female rats and dogs. Solvay Duphar/Hazleton Laboratories Data on File 1960.
  28. Keller JG. Acute subcutaneous administration of SAD 121 to female rats and dogs. Solvay Duphar/Hazleton Laboratories Data on File 1960.
  29. Tusing TW, et al. 34 weeks dietary administration to rats of SAD 121 (isopregnone). Solvay Duphar/Hazleton Laboratories Data on File 1961.
  30. Tusing TW, et al. 32 weeks oral administration (gelatin capsule) to beagle dogs of SAD 121 (five days per week). Solvay Duphar/Hazleton Laboratories Data on File 1961.
  31. Jager FC, Saxena SC. The effects of oral administration of dydrogesterone to male and female beagle dogs for 12 months. Solvay Duphar Data on File 1980.
  32. Ashby R, Finn JP. Dydrogesterone: toxic and tumorigenic potential in rats resulting from dietary administration for 90 weeks. Life Science Report No 79/PHR004/348 1982.
  33. Richold M, Jones E, Fleming PM. Ames metabolic activation test to assess the potential mutagenic effect of dydrogesterone. Solvay Duphar Data on File PDR 365/81586 1982.
  34. Richold M, Richardson JC, Proudlock RJ. Micronucleus test on dydrogesterone. Solvay Duphar Data on File PDR 366/81675 1981.
  35. Englund DE, Johansson EDB. Oral versus vaginal absorption of estra-diol in postmenopausal women. UpsalaJ Med Sci 1981;86:297-307.
  36. Fink BJ, Strid Christensen M. Bioavailability of estradiol and oestriol administered orally to oophorectomized women. Maturitas 1981:3:289-294.
  37. De Vries MH, Raghoebar M, Grahnen A, et al. A study on multiple dose kinetics of dydrogesterone and DHD at 20 mg dydrogesterone and pharmacokinetic interactions between dydrogesterone (20 mg) and estradiol (2 mg) at steady state. Solvay Duphar Data on File H102 6004 1992.
  38. Grahnen A, Eckernas SA. The effects of dydrogesterone on the steady state pharmacokinetics of estradiol in healthy postmenopausal women. SoWay Duphar Data on Frte H 102 6006 1994.
  39. Bolt HM. Metabolism of estrogens - natural and synthetic. Pharmacol Therapeutics 1979; 12:155-181.
  40. Stumpf PG. Pharmacokinetics of estrogen. Obstet Gynecol 1990;75:S9-S14.
  41. Toorop GR Progestational activity of dydrogesterone and its main metabolite, progesterone and medroxy-progesterone in the rabbit. Solvay Duphar Data on File H 102 104 1991.
  42. Mashchak CA, Lobo RA, Dozono-Takano R, Eggena R Nakamura RM, Brenner PF, Mishell DR, Jr. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynaecol 1982:144:511-518.
  43. Archer DF, Fischer LA, Rich D, Schade GH, Schwartz S, Wittcoff H, Clark CS, sr., Maloney K, Smith FO. Estrace® vs Premarin® for treatment of menopausal symptoms: dosage comparison study. Adv Therl992;9:21-31.
  44. Phillips K, Glendon G, Knight JA. Putting the risk of breast cancer in perspective. N Engl J Med 1999:340:141-144.
  45. Campagnoli C, Lesca Lr Cantamessa C, Peris C. Long-term hormone replacement treatment in menopause: new choices, old apprehensions, recent findings. Maturitas 1993; 18:21-46.
  46. Siddle NC, Fraser D, Whitehead Ml, Jesinger DK, Endacott J, Prescott P, Pryse-Davies J. Endometrial, physical and psychological effects of postmenopausal estrogen therapy with added dydrogesterone. Br J ObstGynaecol 1990;97:1101 -1107.
  47. Jager FC, Michielsens PAALJ, Minter B, et al. Summary of the properties of dydrogesterone. Solvay Duphar Data on File H 102 053 1988.
  48. Vermorken AJM, Sultan Cf Coos CMAA. Dydrogesterone has no peripheral (anti)-androgenic properties. In Vivo 1998; 1:167-172.
  49. Oldenhave A, Jaszmann LJB, Haspels AA, Everaerd WTAM. Impact of climacteric on well-being: a survey on 5213 women 39 to 60 years old. Am J Obstet Gynecol 1993;168:772-780.
  50. Zweifel JE, O'Brian WH. A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinol 1997;22:189-212.
  51. Karlberg J, Mattsson L, Wiklund I. A quality of life perspective on who benefits from estradiol replacement therapy. Acta Obstet Gynecol Scand 1999;74:367-372.
  52. Daly E, Vessey M, Barlow D, Gray A, McPherson K, Roche M. Hormone replacement therapy in a risk-benefit perspective. Maturitas 1996;23:247-259.
  53. Clinical Synthesis Panel on HRT. Clinical synthesis conference: Hormone replacement therapy. Lancet 1999;354:152-155.
  54. Kenemans P. Menopause, hormone replacement therapy and menopausal symptoms. J Epidemiol Biostat 1999;4:141-146.
  55. Torgerson DJ, Reid DM. The pharmacoeconomics on hormone replacement therapy. Pharmacoeconomics 1999; 1:9-16.
  56. Amy JJ. femoston®: effects on bone and quality-of-life. Eur Menop J 1995;2(Suppl.):16-22.
  57. De Jonge S, Biesheuvel E. 1-year, double blind, prospectively randomised, multi-centre trial, investigating the efficacy of three continuous combined estradiol-dydrogesterone hormone replacement regimens (1/5, 1/10 and 1/20 mg) in providing endometrial protection. Solvay Pharmaceuticals Report No. H.102.5011.01. 1997.
  58. Haenggi W, Birkhaeuser MH. A new peroral estrogen/progestine combination for postmenopausal hormonal substitution: an open multicentric field study. Maturitas 1993; 16:111 -122.
  59. Von Schoultz B. Longcycle therapy - an option? Eur Menop J 1996;3 (Suppl.):136-140.
  60. Stumpf WE, Sur M, Joshi SE. Estrogen target cells in the skin. Experientia 1976;30:196-198.
  61. BologniaJL, Braverrnan IM, Rousseau ME, Sarrel PM. Skin changes in menopause. Maturitas 1989;! 1:295-304.
  62. Fraser D, Padwick ML, Whitehead Ml, Coffer A, King RJB. Presence of an oestradiol receptorrelated protein in the skin: changes during the normal menstrual cycle. Br J ObstGynaecol 1991;98:1277-1282.
  63. Castelo-Branco C, Durran M, Gonzales-Merlo J. Skin collagen changes related to age and hormone replacement therapy. Maturitas 1992;15:113-119.
  64. Aloia JF, McGowan DM, Vaswani AN, Ross P, Conn SH. Relationship of menopause to skeletal and muscle mass. Am J Clin Nutr 1991;53:1378-1383.
  65. Rauramo L, Punnonen R. The effect of castration and peroral estrogen therapy on a woman's skin. In: Anonymous Ageing and Estrogens. Front.Hormone Res. Basel: Karger, 1973:48-54.
  66. Dunn L, Damesyn M, Moore AA, Reuben DB, Greendale GA. Does estrogen prevent skin aging? Arch Dermatol 1997; 133:399-342.
  67. Brincat M, Moniz CF, Magos A, de Trafford J, Studd JWW Skin collagen changes in postmenopausal women receiving different regimes of estrogen therapy. Obstet Gynecol 1987;70:123-127.
  68. Punnonen R, Vilska S, Rauramo L. Skinfold thickness and long-term post-menopausal hormone therapy. Maturitas 1984;5:259-262.
  69. Meschia M, Bruschi F, Amicarelli F, Barbacini P, Monza G, Crosignani P. Transdermal Hormone replacement therapy and skin in postmenopausal women: A placebo controlled study. J Am Menop Soc 1994;l:79-82.
  70. Maheux R, Naud R, Rioux M, Grenier R, Lamay A, Guy J, Langerin M. A randomised, doubleblind, placebo-controlled study on the effect of conjugated estrogens on skin thickness. Am J Obstet Gynecol 1994;170:642-649.
  71. Brincat MR Hormone replacement therapy and the skin: beneficial effects: the case in favor of it. Acta Obstet Gynecol Scand 2000;79:244-249.
  72. Sauerbronn AVD, Fonseca AM, Bagnoli VR, Saldiva PH, Pinotti JA. The effects of systemic hormonal replacement therapy on the skin of postmenopausal women. Int J Gynecol Obstet 2000;68:35-41.
  73. Rozenbaum H, Birkhauser MH. Consensus propositions. In: Birkhauser MH, Rozenbaum H, eds. Menopause. European Consensus Development Conference. Montreux, Switzerland, 8-10 September 1995. Paris: Editions Eska, 1996:293-303.
  74. Calaf Alsina J. Perception and use of local hormone replacement therapy. Eur Menop J 1996;3( Suppl. ):85-89.
  75. Cardozo L. The role of oestrogens in urogynaecology: Low-dose therapy. In: Birkhauser MH, Rozenbaum H, eds. Menopause. European Consensus Development Conference. Montreux, Switzerland, 8-10 September 1995. Paris: Editions Eska, 1996:59-66.
  76. Fantl JA, Cardozo L, McLish DK, and The Hormones and Urogenital Therapy Committee. Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta-analysis. First report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1994;83:12-18.
  77. Callantine MR, Martin PL, Bolding ОТ, Warner PO, Greaney MOj. Micronized 17ft-estradiol for oral estrogen therapy in menopausal women. Obstet Gynecol 1975;46:37-41.
  78. Те Velde ER, van Leusden HAIM. Hormonal treatment for the climacteric: alleviation of symptoms and prevention of postmenopausal disease. Lancet 1994;343:654-658.
  79. Elia G, Bergman A. Estrogen effects on the urethra: beneficial effects in women with genuine stress incontinence. Obstet Gynecol Surv 1993;48:509-517.
  80. Nichols КС, Schenkel L, Benson H. 17B-Estradiol for postmenopausal estrogen replacement therapy. Obstet Gynecol Sun' 1984;39 (Suppl.4):230-245.
  81. Nilsson K, Heimer G. Low-dose 17ft-oestradiol during maintenance therapy-a pharmacokinetic and pharmacodynamic study. Maturitas 1995;21:33-38.
  82. Gelfand M, Fugere P, Bissonnette F. Cardiovascular risk factors during sequentially combined 17fS-oestradiol and dydrogesterone (femoston®); results from a one-year study in postmenopausal women. Maturitas 1997;26:125-132.
  83. Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L. Meta-analysis of estrogen therapy in the management of urogeni-tal atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1998;92:722-727.
  84. Graziottin A. HRT: the woman's perspective. Int J Gynecol Obstet 1996;52(Suppl. 1):S1-S6.
  85. Lachowsky M. Urinary problems around the menopause; emotional and psychological consequences;can we help our patients to cope with them? Maturitas 2000;34 (Suppl 1 ):S25-S27.
  86. Privette M, Cade R, Peterson J, Mars D. Prevention of recurrent urinary tract infections in postmenopausal women. Nephron 1988;50:24-27.
  87. Calaf Alsina J. The role of oestrogens in urogynaecology: High-dose therapy. In: Birkhauser MH, Rozenbaum H, eds. Menopause. European Consensus Development Conference. Montreux, Switzerland, 8-10 September 1995. Paris: Editions Eska, 1996:51-58.
  88. Kirchengast S, Gruber D, Sator M, Hartmann B, Knogler W, Huber J. Menopause-associated differences in female fat patterning estimated by dual-energy X-ray absorptiometry. Ann Hum Biol 1997;24:45-54.
  89. van Seumeren I. Weight gain and hormone replacement therapy: are women's fears justified? Maturitas 2000;34 (Suppl. 1 ):S3-S8.
  90. Crook D, Godsland IF, Hull J, Stevenson JC. Hormone replacement therapy with dydrogesterone and 17ft-oestradiol: effects on serum lipoproteins and glucose tolerance during 24 month follow up. Br J ObstGynaecol 1997; 104:298-304.
  91. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. J Am Med Ass 1995:273:199-208.
  92. van der Mooren MJ, Demacker PNM, Thomas CMC, Borm GF, Holland R. A 2-year study on the beneficial effects of 17B-oestradiol-dydroges-terone therapy on serum lipoproteins and Lp(a) in postmenopausal women: no additional unfavourable effects of dydrogesterone. Eur J Obstet Gynecol Reprod Biol 1993;52:117-123.
  93. Hanggi W, Lippuner K, Riesen W, Jaeger P, Birkhauser MH. Long term influence of different postmenopausal hormone replacement regimes on serum lipids and lipoprotein(a): a randomized study. Br J Obst Gynaecol 1997;104:708-717.
  94. Hanggi W, Lippuner K, Jaeger P, Birkhauser MH, Horber FF. Differential impact of conventional oral or transdermal hormone replacement therapy or tibolone on body composition in postmenopausal women. Clin Endocrinol 1998:48:691-699.
  95. Cummings SR, Black DM, Newitt MC, et al. Bone density at various sites for prediction of hip fractures. Lancet 1993;341:72-75.
  96. Melton IJI, Lane AW, Cooper C, et al. Hip fractures in the elderly: a worldwide projection. Osteopor Int 1993;3:113-119.
  97. Consensus Development Conference. Diagnosis, prophylaxis, and treatment of osteoporosis. Am Med J 1993;94:646-650.
  98. Riis BJ. How should HRT be used in the prevention and treatment of osteoporosis? In: Birkhauser MH, Rozenbaum H, eds. Menopause. European Consensus Development Conference. Montreux, Switzerland, 8-10 September 1995. Paris: Editions Eska, 1996:111-116.
  99. World Health Organisation. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843. 1994.
  100. Kiel DP, Felson DT, Anderson JJ, Wilson PWF, Moskowitz MA. Hip fracture and the use of estrogens in postmenopausal women: the Framingham study. N Engl J Med 1987;317:1169-1174.
  101. KanisJA, Johnell O, Gullberg B, Allander E, Dilsen G, Gennari C, Vaz AAL, Lyritis GP, Mazzuoli G, Miravet L, Passed M, Cano RP, Ribot C. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. Br Med J 1992;305:1124-1128.
  102. Ettinger B, Genant HK, Steiger P, Madvig P. Low dosage micronized 17|3(5-estradiol prevents bone loss in postmenopausal women. Am J Obstet Gynecol 1992; 166:479-488.
  103. Haenggi W, Lippuner K, Casez J-P, Birkhauser MH, Jaeger R Prevention of postmenopausal bone loss using conventional hormone replacement therapy or ORG OD14. Schweiz Med Wochenschr 1993;123 (Suppl. 50/11 ):A513.
  104. Studd J, Panay N, Zamblera D, Leather AT. HRT and long-term compliance: The efficacy and safety of MenorestR. Int J Gynecol Obstet 1996;52 (Suppl.l):21-25.
  105. Voetberg GA, Netelenbos JC, Kenemans P, Peters-Muller ERA, van de Weijer PHM. Estrogen replacement therapy continuously combined with four different dosages of dydrogesterone: effect on calcium and lipid metabolism. J Clin Endocrinol Metab 1994;79:1465-1469.
  106. De Valk-De Roo GW, Netelenbos JC, Peters-Muller IRA, Voetberg GA, van de Weijer PHM, Bouman AA, Popp-Snijders C, Kenemans P. Continuously combined hormone replacement therapy and bone turnover: the influence of dydrogesterone dose, smoking and initial degree of bone turnover. Maturitas 1997;28:153-162.
  107. Lippuner K, Haenggi W, Birkhaeuser H, Casez J-P, Jaeger P. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 1715-estradiol and dydrogesterone. J Bone Mineral Res 1997;12:806-812.
  108. Lees B, Pugh M, Siddle N, Stevenson JC. Changes in bone density in women starting hormone replacement therapy compared with those in women already established on hormone replacement therapy. Osteopor Int 1995;5:344-348.
  109. van Hoof HJC, van der Mooren MJ, Swinkels LMJW, Rolland R, Benraad TJ. Hormone replacement therapy increases serum 1,25-dihydroxyvitamin D: A 2-year prospective study. Calcif Tissue Int 1994;55:417-419.
  110. Gambacciani M, Ciaponi M, Cappagli B, Piaggesi L, Benussi C, Piccheti S, Genazzani AR. Long-term effects of cyclic combined conjugated estrogens and dydrogesterone in postmenopausal women. In: Wren BG, ed. Progress in the Management of the Menopause. The Proceedings of the 8th Congress on the Menopause. Sydney, Australia, November 1996. New York, London: Parthenon Publishing, 1997:432-437.
  111. Stevenson JC, Teter P, Lees B. 1715-oestradiol (1 mg/day) continuously combined with dydrogesterone (5, 10 or 20 mg/day) increases bone mineral density in postmenopausal women. Submitted 2000.
  112. Quigley MET, Martin PL, BurnierAM, Brooks R Esirogen therapy arrests bone loss in elderly women. Am J Obstet Gynecol 1987; 156:1516-1523.
  113. Marx CW, Dailey GB, Cheney C, Vint VC, Muchmore DB. Do estrogens improve bone mineral density in osteoporotic women over age 65? J Bone Mineral Res 1992:7:1275-1279.
  114. Naesse'n T, Persson I, Adami HO, Bergstrom R, Bergkvist L. Hormone replacement therapy and the risk for first time hip fracture. A prospective, population based cohort study. Ann Intern Med 1990:1 13:95-103.
  115. Cauley JA, Seeley DG, Ensrud K. Estrogen replacement therapy and fractures in older women. Ann Intern Med 1995:122:9-16.
  116. Fletcher JLM, Vessey MR Coronary heart disease in women: Current trends and health economics. In: Birkhauser MH, Rozenbaum H, eds. Menopause. European Consensus Development Conference. Montreux, Switzerland, 8-10 September 1995. Paris: Editions Eska, 1996:139-150.
  117. Anonymous. Coronary Heart Disease: an Epidemiological Overview. Department of Health. London. 1994.
  118. StampferMJ, Colditz GA. Menopause and heart disease: a review. Ann NY AcadSci 1990:592:193-203.
  119. Godsland IF. Anti- atherosclerotic effects of oestrogens. In: Birkhauser MH, Rozenbaum H, eds. Menopause. European Consensus Development Conference. Montreux, Switzerland, 8-10 September 1995. Paris: Editions Eska, 1 996: 1 6 1 - 1 70.
  120. Speroff L. The effect of oestrogen-progestogen postmenopausal hormone replacement therapy on the cardiovascular system. Eur Menop J 1996:3 (Suppl. ):151-163.
  121. Mijatovic V, van der Mooren MJ, Stehouwer CDA, Netelenbos JC, Kenemans P. Postmenopausal hormone replacement, risk estimators for coronary artery disease and cardiovascular protection. Gynecol Endocrinol 1999;13:130-144.
  122. Chae CU, Ricker PM, Manson JAE. Postmenopausal hormone replacement therapy and cardiovascular disease. Thrombos Haemostas 1997;78:770-780.
  123. Rosano CMC, Chierchia SL, Leonardo F, Beale CM, Collins P. Cardioprotective effects of ovariar hormones. Eur Heart J 1996:17 (Suppl.
  124. Tagawa H, Shimokawa H, Tagawa T, Kuroiwa-Matsumoto M, Hirooka Y, Takeshita A. Shortterm estrogen augments both nitric oxidemediated and nonnitric oxidemediated endothelium-dependent forearm vasodiation in postmenopausal women. J Cardiovasc Pharmacol 1997:30:481-488.
  125. Grodstein F, StampferMJ. Selection bias and studies of hormone replacement therapy. In: Birkhauser MH, Rozenbaum H, eds. Menopause. European Consensus Development Conference. Montreux, Switzerland, 8-10 September 1 995. Paris: Editions Eska, 1 996: 1 5 1 - 1 56.
  126. Bush TL, Miller-Bass K. Estrogen therapy and cardiovascular disease: do the benefits outweigh the risks? Clin Obst Gynecol 1991:5:889-913.
  127. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiological evidence. PrevMed 1991:20:47-63.
  128. Sullivan JM, Fowlkes LP. The clinical aspects of estrogen and the cardiovascular system. Obstet Gynecol 1996:87:365-435.
  129. Barrett-ConnorE, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998:19:55-72.
  130. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Croup. J Am Med Ass 1998;280:605-613.
  131. Meade TW, Vickers MR. Hormone replacement therapy and cardiovascular disease. J Epidemiol Biostat 1 999:4: 1 65- 1 90.
  132. van Beresteijn ECH, Korevaar JC, Huijbregts PCW, Schouten EG, BuremaJ, Kok FJ. Perimenopausal increase in serum cholesterol: a 10-year longitudinal study. Am J Epidemiol 1993:137:383-392.
  133. Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 1993:98:83-90.
  134. Lobo RA, Speroff L. International consensus conference on postmenopausal hormone therapy and the cardiovascular system. FertSteril 1994:61:592-595.
  135. Jensen MD, Martin ML, Cryer PE, Roust LR. Effects of estrogen on free fatty acid metabolism in humans. Am J Physiol 1994;266:E914-920.
  136. Campos H, Sacks FM, Walsh BW, Schiff I, O'Hanesian MA, Krauss RM. Differential effects of estrogen on low-density lipoprotein subclasses in healthy postmenopausal women. Metabolism 1993;42:1 153-1 158.
  137. van Baal WM, Kooistra T, Stehouwer CD. Cardiovascular Disease Risk and Hormone Replacement Therapy (HRT): A Review Based on Randomised, Controlled Studies in Postmenopausal Women. Curr MedChem2000;7:499-517.
  138. Manolio ТА, Furberg CD, Schemanski L, Psaty BM, O'Leaary DH, Tracy RP, Bush TL. Associations of postmenopausal oestrogen use with cardiovascular disease and its risk factors in older women. Circulation 1993:88:2163-2171.
  139. Samsioe G, Astedt B. Does progestogen co-medication attenuate the cardiovascular benefits of oestrogens? In: Birkhauser MH, Rozenbaum H, eds. Menopause. European Consensus Development Conference. Montreux, Switzerland, 8-10 September 1995. Paris: Editions Eska, 1996:175-184.
  140. Rijpkema AHM, van der Sanden AA, Ruijs AHC. Effects of postmenopausal estrogen-progestogen replacement therapy on serum lipids and lipoproteins. A review. Maturitas 1990:12:259-285.
  141. Crook D, Gust MP, Gangar KF, Worthington M, Hillard TC, Stevenson JC, Whitehead Ml, Wynn V. Comparison of transdermal and oral oestradiol/progestin hormone replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol 1992; 166:950-955.
  142. Stevenson JC. Do we need different galenic forms of oestrogens and progestogens? In: Birkhauser MH, Rozenbaum H, eds. Menopause. European Consensus Development Conference. Montreux, Switzerland, 8-10 September 1995. Paris: Editions Eska, 1996:231-236.
  143. Rozenbaum H. How to choose the correct progestogen. In: Birkhauser MH, Rozenbaum H, eds. Menopause. European Consensus Development Conference. Montreux, Switzerland, 8-10 September 1995. Paris: Editions Eska, 1996:243-256.
  144. Lacey RW, Howson CL, Sampson GA. Safety of progestins: effects of dydrogesterone on blood lipids. Br J Clin Pract 1982;Suppl. 24:4-10.
  145. Siddle N, Jesinger D, Whitehead M, Turner P, Lewis B, Prescott R Effect on plasma lipids and lipoproteins of postmenopausal oestrogen therapy with added dydrogesterone. Br J Obst Gynaecol 1990:97:1093-1100.
  146. Gelfand MM, Fugere P, Bissonnette F, Wiita B, Yang H-M, Lorrain J, Ferenczy A. Conjugated estrogens combined with sequential dydrogesterone or medroxyprogesterone actetate in postmenopausal women: effects on lipoproteins, glucose tolerance, endometrial histology, and bleeding. Menop 1997:4:10-18.
  147. Crook D. Multicentre evaluation of 17~-oestradiol and dydrogesterone HRT on cardiovascular risk (Abstract no. F200). 8th International Congress on the Menopause. Sydney, Australia, Nov, 3-7, 1996. 1996.
  148. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991:325:1196-1204.
  149. Pornel B, Chevalier O, Netelenbos JC. Continuous combined oral 1715-estradiol/dydrogesterone improves the serum lipid profile of postmenopausal women. Submitted to J Clin Endocrinol Metab 2000.
  150. Jesinger DK. Are conjugated oestrogens (GEE) 0.625 mg and 1 mg oestradiol (E2) comparable? (Abstract) IV. European Congress on Menopause. Vienna, Austria, 8 - 12th October, 1997.
  151. Godsland IF. The influence of female sex steroids on glucose metabolism and insulin action. J Intern Med 1996;240 (Suppl. 738): 1-60.
  152. Stout RW. Insulin resistance, hyperinsulinemia, dyslipidemia and atherosclerosis. In: Moller DE, ed. Insulin resistance. New York: Wiley, 1993:354-384.
  153. Gaspard UJ, Gottal J, van den Brule FA. Postmenopausal changes of lipid and glucose metabolism: a review of their main aspects. Maturitas 1995:21:171-178.
  154. Crook D, Godsland IF, Stevenson JC. The cardiovascular risk profile of hormone replacement therapies containing dydrogesterone: a review. Eur Menop J 1995;2(Suppl.):23-30.
  155. Fahraeus L. Metabolic consequences of postmenopausal estrogen and progestogen treatment. Acta Obstet Gynecol Scand 1985; 172 (Suppl.):19-21.
  156. Godsland IF, Gangar K, Walton C, Gust MP, Whitehead Ml, Wynn V, Stevenson JC. Insulin resistance, secretion and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 1993;42:846-853.
  157. De Cleyn K, Buytaert P, Delbeke L, Gerris J. Equine estrogen-dydrogesterone therapy in the management of postmenopausal women. Eur J Obstet Gynecol Reprod Biol 1986;23:201 -209.
  158. Erkkola RU, Hirvonen EJ, Juntunen KST, Saastamoinen JS, Tuimala RJ, Rinne RM, Paakkari ATI. Comparison of transdermal to oral hormone replacement therapy. Effects on lipid and carbohydrate metabolism, and on antithrombin III, fibrinogen, renin substrate and sex-hormone binding globulin. Eur Menop J 1995;2:21-27.
  159. Crook D, Godsland IF, Stevenson JC, Siddle NC. Cardiovascular risk markers in postmenopausal women using estradiol and dydrogesterone progestin. Int J Gynecol Obstet 1994:46 (Suppl.l):Abstract PO20.11.
  160. Gaspard UJ, Wery OJ, Scheen AJ, Jaminet C, Lefebvre RJ. Long-term effects of oral estradiol and dydrogesterone on carbohydrate metabolism in postmenopausal women. Climacteric 1999;2:93-100.
  161. Godsland IF. Principles and practice of hormone replacement therapy in women with manifest diabetes. Eur Menop J 1996;3 (Suppl.): 106-111.
  162. Stevenson JC, Godsland IF. Hormone replacement therapy in diabetes. In: Wren BG, ed. Progress in the Management of the Menopause. The Proceedings of the 8th International Congress of the Menopause. Sydney, Australia, November 1996. New York, London: The Parthenon Publishing Group, 1997:315-322.
  163. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham IM. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991:324:1149-1155.
  164. Stampfer MJ, Manilow MR, Willett WC, et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. J Am Med Ass 1992:268:877-881.
  165. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AC. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. J Am Med Ass 1995:274:1049-1057.
  166. Manilow MR. Homocyst(e)ine and arterial occlusive disease. J Intern Med 1994;236:603-617.
  167. Wouters MGAJ, Moorees MTEC, van der Mooren MJ, et al. Plasma homocysteine and menopausal status. Eur J Clin Invest 1995;25:801-805.
  168. van der Mooren MJ, Wouters MGAJ, Blom HJ, Schellekens LA, Eskes TKAB, Rolland R. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. Eur J Clin Invest 1994;24:733-736.
  169. Mijatovic V, Kenemans P, Netelenbos C, Jakobs C, Popp-Snijders C, Peters-Muller ER, van der Mooren MJ. Postmenopausal oral 1715-estradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels. FertSteril 1998:69:876-882.
  170. Mijatovic V, Kenemans P, Jakobs C, van Baal WM, Peters-Muller ER, van der Mooren MJ. A randomized controlled study of the effects of 17B-estradiol-dydrogesterone on plasma homocysteine in postmenopausal women. Obstet Gynecol 1998:91:432-436.
  171. Winkler UH. Menopause, hormone replacement therapy and cardio-cascular disease: a review of haemostaseological findings. Fibrinolysis 1992;6 (Suppl. 3):5-10.
  172. Lindoff C, Peterson F, Lecander I, Martinsson G, Astedt B. Passage of the menopause is followed by haemostatic changes. Maturitas 1993;17:17-22.
  173. Meade TW, Dyer S, Howarth DJ, Imeson JD, Stirling Y. Antithrombin III and procoagulant activity: sex differences and effects on the menopause. BrJ Haematol 1990;74:77-81.
  174. Daly E, Vessey A/IP, Hawkins MM, et al. Risk of venous thromboem-bolism in users of hormone replacement therapy. Lancet 1999:348:977-980.
  175. Jick H, Derby LE, Wald Myers M, et al. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996;348:981-983.
  176. Grodstein F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Speizer FE, Willett WC, Hennekens CH. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996:348:983-987.
  177. Notelovitz M, Kitchens C, Ware M, Hirschberg K, Coone L. Combination estrogen and progestogen replacement therapy does not adversely affect coagulation. Obstet Gynecol 1983;62:596-600.
  178. Lindoff С, Peterson F, Lecander I, Martinsson G, Astedt B. Transdermal oestrogen replacement therapy: beneficial effects on haemostatic risk factors for cardiovascular disease. Maturitas 1996;24:43-50.
  179. Devor M, Barrett-Connor E, Renvall M, Feigal D, Ramsdell J. Estrogen replacement therapy and the risk of venous thrombosis. Am J Med 1992:92:275-282.
  180. van der Mooren MJ, Demacker PNM, Thomas CMC, Rolland R. Beneficial effects on serum lipoproteins by 1715-oestradiol-dydroges-terone therapy in postmenopausal women: a prospective study. Eur J Obstet Gynecol Reprod Biol 1992;47:153-160.
  181. van Baal WM, Kenemans P, Emels 11, Schalkwijk CG, Mijatovic V, van der Mooren MJ, Vischer DM, Stehouwer CDA. Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women. FertSteril 1999;71:663-670.
  182. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. J Am Med Ass 1996;275:1571 -1576.
  183. Kannel WB, Wilson PW. Risk factors that attenuate the female coronary disease advantage. Arch Intern Med 1995:155:57-61.
  184. Staessen J, Bulpitt CJ, Fagard R, Lijnen P, Amery A. The influence of menopause on blood pressure. J Hum Hypertens 1989:3:427-433.
  185. van Ittersum FJ, van Baal WM, Kenemans P, Mijatovic V, Donker AJM, van der Mooren MJ, Stehouwer CDA. Ambulatory -not office-blood pressures decline during hormone replacement therapy in healthy postmenopausal women. Am J Hypertens 1998:11:1147-1152.
  186. Birge SJ. Maintaining mental health with hormone replacement therapy. Eur Menop J 1996;3(Suppl.):164-169.
  187. Jorm AF, Korten AE, Henderson AS. The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand 1987:76:465-479.
  188. Skoog I, Gustafson D. Hormone replacement therapy and dementia. J Epidemiol Biostat 1999:4:227-251.
  189. Notelovitz M. Hormone replacement therapy - benefits versus risks. Eur Menop J 1996;3 (Suppl.): 186-196.
  190. Jaffe AB, Toran-Allerand CD, Greengard P, Gandy SE. Estrogen regulates metabolism of Alzheimer amyloid B-precursor protein. J Biol Chem 1994:269:13065-13068.
  191. Manly JJ, Merchant CA, Jacobs DM, Small SA, Bell K, Ferin M, Mayeux R. Endogenous estrogen levels and Alzheimer's disease among postmenopausal women. Neurology 2000;54:833-837.
  192. Sherwin BB, Phillips S. Estrogen and cognitive functioning in surgically menopausal women. Ann NY Acad Sci 1990;592:474-475.
  193. Phillips S, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinol 1991:17:485-495.
  194. van Hulle R, Demol R. A double-blind study into the influence of estri-ol on a number of psychological tests in postmenopausal women. In: van Keep PA, Greenblatt RB, Albeaux-Fernet M, eds. Consensus on Menopausal Research. London: MTP Press, 1976:94-99.
  195. Fedor-Freyberg P. The influence of oestrogens on the wellbeing and mental performance in climacteric and postmenopausal women. Acta Obstet Gynecol Scand 1977;64:3-69.
  196. Kampen DL, Sherwin BB. Estrogen use and verbal memory in healthy postmenopausal women. Obstet Gynecol 1994:83:979-983.
  197. Robinson D, Friedman L, Marcus R, Tinklenberg J, Yesavage J. Estrogen replacement and memory in older women. J Am Geriatr Soc 1994:42:919-922.
  198. Kimura D. Estrogen replacement therapy may protect against intellectual decline in postmenopausal women. Horm Behav 1995:29:312-321.
  199. Barrett-Connor E, Kritz-Silverstein D. Estrogen replacement therapy and cognitive function in older women. J Am Med Ass 1993:260:2637-2641.
  200. Resnick SM, Metter EJ, Zonderman AB. Estrogen replacement therapy and longitudinal decline in visual memory. A possible protective effect? Neurology 1997;49:1491-1497.
  201. Fillit H, Weinref H, Cholst I, Luine V, McEwen B, Amador R, Zabriskie J. Observations in a preliminary open trial of estradiol therapy for senile dementia -Alzheimer's type. Psychoneuroendocrinol 1986:11:337-345.
  202. Honjo H, Ogino Y, Naitoh K, Urabe M, Kitawaki J, Yasuda J, Yamamoto T, Ishihara S, Okada H, Yonezawa T, Hayashi K, Nambara T. In vivo effects by estrone sulfate on the central nervous system-senile dementia (Alzheimer's type). J Steroid Biochem 1989:34:521-525.
  203. Honjo H, Ogino Y, Tanaka K, Urabe M, Kashiwagi T, Ishihara S, Okada H, Araki K, Fushiki S, Nakajima K, Hayashi K, Hayashi M, Sasaki T. An effect of conjugated estrogen to cognitive impairment in women with senile dementia -Alzheimer's type: A placebo-controlled double blind study. J Jpn Menopause Soc 1993:1:167-171.
  204. Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975;293:1167-1170.
  205. Brinton LA, Hoover RN. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. Obstet Gynecol 1993:81:265-271.
  206. Shapiro S, Kelly JP, Rosenberg L, Kaufman DW, Helmrich SP, Rosenshein NB, Lewis JL, jr., Knapp RC, Stolley PD, Schottenfeld D. Risk of localized and widespread endometrial cancer in relation to - recent and discontinued use of conjugated estrogens. N Engl J Med 1985:313:969-972.
  207. Rose PC. Endometrial carcinoma. N Engl J Med 1996:335:640-649.
  208. Hunt K, Vessey M, McPherson K, Coleman M. Longterm surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. BrJ Obst Gynaecol 1987;94:620-635.
  209. Rubin GL, Peterson HB, Lee NC, Maes EF, Wingo PA, Becker S. Estrogen replacement therapy and the risk of endometrial cancer: remaining controversies. Am J Obstet Gynecol 1990:162:148-154.
  210. Paganini-Hill A, Ross RK, Henderson BE. Endometrial cancer and pattern of use of estrogen replacement therapy. A cohort study. Br J Cancer 1989:59:445-447.
  211. Schneider HPG. Which data exist: state-of-the-art. In: Birkhauser MH, Rozenbaum H, eds. Menopause. European Consensus Development Conference. Montreux, Switzerland, 8-10 September 1995. Paris: Editions Eska, 1996:193-206.
  212. Grady D, Gebretsadik T, Kerlikowske K, ErnsterV, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85:304-313.
  213. Weiderpass E, Adami HO, Baron JA, Magnusson C, Bergstrom R, Lindgren A, Correia N, Persson I. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999;91:1131-1137.
  214. Varma TR. Effect of long-term therapy with estrogen and progesterone on the endometrium of postmenopausal women. Acta Obstet Gynecol Scand 1985:64:41-46.
  215. Whitehead M, Lobo RA. Consensus conference: progestagen use in postmenopausal women. Lancet 1988;11:1243-1244.
  216. van derMooren MJ, Hanselaar AGJM, Borm GF, Holland R. Changes in the withdrawal bleeding pattern and endometrial histology during 17B-estradiol - dydrogesterone therapy in postmenopausal women: a 2 year prospective study. Maturitas 1995)20:175-180.
  217. Burch DJ, Spowart KJW, Jesinger DK, Randall S, Smith SK. A dose-ranging study of the use of cyclical dydrogesterone with continuous 1715-oestradiol. BrJ Obst Gynaecol 1995; 102:243-248.
  218. Hanggi W, Bersinger N, Altermatt HJ, BirkhauserMH. Comparison of transvaginal ultrasonography and endometrial biopsy in endometrial surveillance in postmenopausal HRT users. Maturitas 1997;27:133-143.
  219. Ferenczy A, Gelfand MM. Endometrial histology and bleeding pattern in post-menopausal women taking sequential, combined estradiol and dydrogesterone. Maturitas 1997;26:219-226.
  220. van de Weijer PHM, Scholten P, van der Mooren MJ, Barentsen R, Kenemans R Bleeding patterns .and endometrial histology during administration of low dose estradiol sequentially combined with dydrogesterone. Climacteric 1999;2:l-9.
  221. Bergeron C, Ferenczy A. Endometrial safety of continuous combined hormone replacement therapy with 17f3-oestraidol (1 or 2 mg) and dydrogesterone. submitted 2000.
  222. Korhonen MO, Symons JP, Hyde BM, Rowan IP, Wilborn WH. Histologic classification and pathologic findings for endometrial biopsy specimens obtained from 2964 perimenopausal and postmenopausal women undergoing screening for continuous hormones as replacement therapy (CHART 2 Study). Am J Obstet Gynecol 1997; 176:377-380.
  223. Notelovitz M, Varner RE, Rebar RW. Minimal endometrial proliferation over a two-year period in postmenopausal women taking 0.3 mg of unopposed esterified estrogens. Menop 1997;4:80-88.
  224. Committee for Proprietary Medicinal Products (CPMP). Points to consider on HRT. London, 19 November 1997. 1997.
  225. Quereux C. A one-year open multi-center study investigating the efficacy of a continuous combined 17ft-estradiol/dydrogesterone hormone replacement regimen (E2 1 mg/D 5 mg) in providing endome-trial protection in postmenopausal women. Solvay Pharmaceuticals Data on file Report No SI02.3.107. 2000.
  226. Eraser IS. A review of the role of progestogens in hormonal replacement therapy: influence on bleeding patterns. Maturitas 1986:8:113-121.
  227. AI-Azzawi F, Habiba M. Regular bleeding on hormone replacement therapy, a myth? BrJ Obst Gynaecol 1994; 101:661-662.
  228. Hahn RG. Compliance considerations with estrogen replacement: withdrawal bleeding and other factors. Am J Obstet Gynecol 1989:161:1854.
  229. Nachtigall LE. Enhancing patient compliance with hormone replacement therapy at menopause. Obstet Gynecol 1990;75 (Suppl.):S77-S80.
  230. van de Weijer PHM, Barentsen R, De Vries MH, Kenemans P. Relationship of estradiol levels to breakthrough bleeding during continuous combined hormone replacement therapy. Obstet Gynecol 1999;93:551-557.
  231. Anonymous. Investigational compound: estradiol - dydrogesterone. Solvay Pharmaceuticals 1999;lnt. Doc. No.
  232. Gambrell RD. Breast disease in the postmenopausal years. Sem Reprod Endocrinol 1983; 1:27-40.
  233. Bergkvist L, Perrson I. Hormone replacement therapy and breast cancer: a review of current knowledge. Drug Safety 1996; 15:360-370.
  234. Musgrove EA, Sutherland RL. Steroidal control of cell proliferation in the breast and breast cancer. In: Wren BG, ed. Progress in the Management of the Menopause. The Proceedings of the 8th International Congress of the Menopause, Sydney, Australia, November 1996. New York, London: The Parthenon Publishing Group, 1997:194-202.
  235. Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack MM, Flanders D, Berkelman RL. A meta-analysis of the effects of oestrogen replacement therapy and the risk of breast cancer. J Am Med Ass 1991:265:1985-1990.
  236. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Gumming SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992:117:1016-1037.
  237. Sillero-Arenas M, Delgado Rodriguez M, Rodigues-Canteras R, Bueno-Cavanillas A, Galvez-Vargas R. Menopausal hormone replacement therapy and breast cancer: a meta-analysis. Obstet Gynecol 1992:79:286-294.
  238. Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: results from epidemiological studies. Am J Obstet Gynecol 1993:168:1473-1480.
  239. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE. The use of estro-gens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-1593.
  240. Colditz GA, Willett WC, Speizer FE. Reply to letters to the editor. N EnglJMed 1995:333:1357-1358.
  241. Schairer C, Byrne C, Keyl PM, Brinton LA, Sturgeon SR, Hoover RN. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control 1994:5:491-500.
  242. Collaborative Group on Hormone Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 1997:350:1047-1059.
  243. LaCroix AZ, Burke W. Breast cancer and hormone replacement therapy. Lancet 1997:350:1042-1043.
  244. Schairer C, Lubin J, Troisi R, Stugeon S, Brinton L, Hoover R, Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. J Am Med Ass 2000:283:485-491.
  245. Speroff L. Postmenopausal estrogen-progestin therapy and breast cancer: A clinical response to an epidemiologic report. Contempor Obstet Gynecol 2000:103-122.
  246. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328-332.
  247. Magnusson C, Baron JA, Correia N, Bergstrom R, Adami H, Persson I. Breast-cancer risk following long-term oestrogen - and oestrogen-progestin-replacement therapy. Int J Cancer 1999:81:339-344.
  248. International Medical Benefit/Risk Foundation Workshop. Hormone replacement therapy (HRT) and breast cancer risk. Pharmacoepidemiol Drug Safety 1993:2:103-105.
  249. Editorial. Assessing the odds. Lancet 1997:350:1563.
  250. Pilote L, Hlatky MA. Attitudes of women toward hormone therapy and prevention of heart disease. Am Heart J 1995:129:1237-1238.
  251. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991; 151:75-78.
  252. Calle ЕЕ, Miracle-McMahill HL, Thun MJ, Heath CW, Jr. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst 1995:87:517-523.
  253. Newcomb PA, Storer BE. Postmenopausal hormone use and risk of large-bowel cancer. J Natl Cancer Inst 1995:87:1067-1071.
  254. Franceschi S, La Vecchia C. Colorectal cancer and hormone replacement therapy: an unexpected finding. Eur J Cancer Prev 1998:7:427-438.
  255. Druckmann R, Ruby J. HRT treatment in menopause - It's time for a more differentiated approach. Menop Rev 1999:4:1-4.
  256. Brzezinski A. A 'menopause score' for postmenopausal hormone replacement therapy. Int J Gynecol Ob stet 1994:44:284-286.
  257. De Vries MH and Van Bemmel P. Multiple dose pharmacokinetics of 1 mg micronised estradiol formulations in healthy postmenopausal women. Solvay Duphar Data on file H.I02.5010 1994.



Solvay Pharma
Баннерная сеть Солвей-Фарма.ру
Адрес


Последнее обновление  26.06.2008 г.